Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (251-260 of 353) with videos related to

Pageof 36
Sort By:
Journal of the American College of Cardiology|February 21, 2006
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromesSunil V Rao, Kristi O'Grady, Karen S Pieper, et al.
European Heart Journal|September 2, 2015
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trialsJacob A Udell, Marc P Bonaca, Jean-Philippe Collet, et al.
Journal of the American College of Cardiology|July 25, 2009
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trialAbhiram Prasad, Bernard J Gersh, Michel E Bertrand, et al.
Journal of the American College of Cardiology|February 21, 2004
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trialHitinder S Gurm, A Michael Lincoff, David Lee, et al.
Journal of the American College of Cardiology|November 22, 2008
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromesDuane S Pinto, Gregg W Stone, Chunxue Shi, et al.
Diabetes Research and Clinical Practice|January 26, 2024
Impact of age on the predictive value of NT-proBNP in patients with diabetes mellitus stabilised after an acute coronary syndromeStefano Savonitto, Nuccia Morici, Silvia Pancani, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 18, 2012
Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experienceOlcay Aksoy, E Murat Tuzcu, Stephen G Ellis, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 28, 2020
Association of adoption of transradial access for percutaneous coronary intervention in ST elevation myocardial infarction with door-to-balloon timeChetan P Huded, Samir R Kapadia, Jad A Ballout, et al.
Clinical Cardiology|August 25, 2020
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)Calvin C Sheng, Debasis Sahoo, Siddharth Dugar, et al.
European Heart Journal|December 25, 2004
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trialsMarino Labinaz, Jasmine Mathias, Karen Pieper, et al.
Pageof 36

Showing results (251-260 of 353) with videos related to

Sort By:
Pageof 36
Journal of the American College of Cardiology|February 21, 2006
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromesSunil V Rao, Kristi O'Grady, Karen S Pieper, et al.
European Heart Journal|September 2, 2015
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trialsJacob A Udell, Marc P Bonaca, Jean-Philippe Collet, et al.
Journal of the American College of Cardiology|July 25, 2009
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trialAbhiram Prasad, Bernard J Gersh, Michel E Bertrand, et al.
Journal of the American College of Cardiology|February 21, 2004
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trialHitinder S Gurm, A Michael Lincoff, David Lee, et al.
Journal of the American College of Cardiology|November 22, 2008
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromesDuane S Pinto, Gregg W Stone, Chunxue Shi, et al.
Diabetes Research and Clinical Practice|January 26, 2024
Impact of age on the predictive value of NT-proBNP in patients with diabetes mellitus stabilised after an acute coronary syndromeStefano Savonitto, Nuccia Morici, Silvia Pancani, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 18, 2012
Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experienceOlcay Aksoy, E Murat Tuzcu, Stephen G Ellis, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 28, 2020
Association of adoption of transradial access for percutaneous coronary intervention in ST elevation myocardial infarction with door-to-balloon timeChetan P Huded, Samir R Kapadia, Jad A Ballout, et al.
Clinical Cardiology|August 25, 2020
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)Calvin C Sheng, Debasis Sahoo, Siddharth Dugar, et al.
European Heart Journal|December 25, 2004
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trialsMarino Labinaz, Jasmine Mathias, Karen Pieper, et al.
Pageof 36